The impact of migraine on daily activities: effect of topiramate compared with placebo

Silberstein, Stephen D.; Loder, Elizabeth; Forde, Grace; Papadopoulos, George; Fairclough, Diane L.; Greenberg, Steven J.

doi:10.1185/030079906x104731

Cited by 34 publications

(29 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such experiments have not been carried out, although a significant effect of migraine medication with triptans versus placebo on self-reported work productivity was documented in a randomized clinical trial (58) and significant before-after reductions in sickness absence were documented in several open-label studies of migraine treatment in workplace samples (59-62). These results suggest that large-scale workplace effectiveness trials are warranted for workers with frequent or severe migraines.…”

Section: Discussionmentioning

confidence: 99%

The associations of migraines and other headaches with work performance: Results from the National Comorbidity Survey Replication (NCS-R)

et al. 2010

View full text Add to dashboard Cite

It is unknown if comorbid conditions account for the association between migraines and work performance. This issue was investigated in the National Comorbidity Survey Replication (n = 9,282). Twelve-month severe or persistent migraines and other headaches were assessed with comorbid 12-month mental and physical disorders using the WHO Composite International Diagnostic Interview. Work performance was assessed using the WHO Health and Work Performance Questionnaire. Significant associations of these conditions with work disability disappeared with controls for comorbid disorders, but severe or persistent migraines continued to predict work loss days even with controls. Individual-level and societal-level annually human capital values were $1,165 and $9.3 billion for this subset of migraines. Roughly 20% of these associations were due to comorbidity, 60% to direct effects, and 20% to indirect effects through temporally secondary comorbidities. These strong associations suggest that workplace interventions for severe or persistent migraines might have a positive return-on-investment for employers.

show abstract

Section: Discussionmentioning

confidence: 99%

The associations of migraines and other headaches with work performance: Results from the National Comorbidity Survey Replication (NCS-R)

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[38,39] Clinical trials have demonstrated that the antiepileptic medications topiramate and divalproex sodium are effective for migraine prophylaxis. Topiramate is efficacious across a broad range of migraine frequencies [40][41][42] and has been associated with improvements in the performance of daily activities and QOL in episodic [43][44][45] and chronic migraine, as assessed by the MSQ. [46] The most common adverse effects associated with topiramate treatment include paraesthesia, fatigue, appetite loss and difficulty concentrating.…”

Section: The Role Of Migraine Preventionmentioning

confidence: 99%

Migraine and Functional Impairment

Brandes

2009

CNS Drugs

View full text Add to dashboard Cite

Migraine is a leading cause of disability worldwide; approximately half of those affected have such severe attacks that they cannot function normally in routine daily activities. Research is beginning to focus upon the burden of migraine between attacks, referred to as interictal burden. This burden encompasses worry and expectation of future attacks that consequently may be associated with limitations in social and family interactions, as well as work capacity. This review aims to increase physician awareness of the degree and scope of functional impairment associated with migraine. Physicians are in a position to assess the true impact of migraine in their patients using techniques such as open-ended questions during visits, and paper-based migraine assessment tools such as the Migraine Disability Assessment questionnaire. Eliciting such information on interictal burden may help the physician prescribe the most appropriate therapy based on their patients' degree of impairment. This article also describes the instruments most widely used for measuring migraine-related functional impairment, summarizes studies assessing the effects of migraine on indicators of health-related quality of life and presents data on how preventive migraine treatment may beneficially influence migraine-related functional impairment.

show abstract

“…Topiramate 100 mg per day also improves daily activity outcomes 46 . This post hoc analysis involved 2 validated quality‐of‐life instruments – one disease‐specific, the Migraine‐Specific Questionnaire (MSQ), and one nondisease‐specific, the SF‐36.…”

Section: Topiramatementioning

confidence: 99%

Neuromodulators for Migraine Prevention

Kaniecki

2008

Headache

View full text Add to dashboard Cite

Migraine is a debilitating condition characterized by a cycle of painful headaches and headache-related symptoms interspersed with periods of worry, distress, and apprehension. The negative impact of migraine on patient functioning, workplace productivity, and other daily activities has been demonstrated through the use of a variety of clinician- and patient-reported assessment tools, including the Migraine-Specific Questionnaire and the Migraine Disability Assessment questionnaire. In addition to considering the frequency and severity of migraine, clinicians need to encourage more open dialogue with their patients about the impact of this disorder on daily activities and productivity. Only then can the most appropriate course of treatment be determined. Appropriately prescribed acute and preventive therapies should break the cycle of migraine and improve the daily activities of patients with this chronic condition. Divalproex sodium and topiramate are neuromodulators that are approved by the US Food and Drug Administration (FDA) for the prophylaxis (prevention) of migraine headache in adults. Non-FDA-approved neuromodulators sometimes used in the management of migraine headache include gabapentin, lamotrigine, levetiracetam, and zonisamide. All medications need to be titrated, and treatment-related adverse events need to be managed appropriately. Preventive medications should be taken for at least 2-3 months to ascertain their therapeutic effect.

show abstract

The impact of migraine on daily activities: effect of topiramate compared with placebo

Cited by 34 publications

References 11 publications

The associations of migraines and other headaches with work performance: Results from the National Comorbidity Survey Replication (NCS-R)

The associations of migraines and other headaches with work performance: Results from the National Comorbidity Survey Replication (NCS-R)

Migraine and Functional Impairment

Neuromodulators for Migraine Prevention

Contact Info

Product

Resources

About